- Home
- ADN vs MYNZ Comparison
ADN vs MYNZ Comparison
Compare ADN & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADN
- MYNZ
- Stock Information
- Founded
- ADN 2006
- MYNZ 2021
- Country
- ADN United States
- MYNZ Germany
- Employees
- ADN N/A
- MYNZ N/A
- Industry
- ADN Power Generation
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- ADN Utilities
- MYNZ Health Care
- Exchange
- ADN Nasdaq
- MYNZ Nasdaq
- Market Cap
- ADN 6.6M
- MYNZ 7.6M
- IPO Year
- ADN N/A
- MYNZ 2021
- Fundamental
- Price
- ADN $1.99
- MYNZ $2.04
- Analyst Decision
- ADN
- MYNZ Buy
- Analyst Count
- ADN 0
- MYNZ 2
- Target Price
- ADN N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- ADN 80.2K
- MYNZ 185.7K
- Earning Date
- ADN 08-19-2025
- MYNZ 08-05-2025
- Dividend Yield
- ADN N/A
- MYNZ N/A
- EPS Growth
- ADN N/A
- MYNZ N/A
- EPS
- ADN N/A
- MYNZ N/A
- Revenue
- ADN $670,000.00
- MYNZ $893,991.00
- Revenue This Year
- ADN $6,528.51
- MYNZ $26.06
- Revenue Next Year
- ADN N/A
- MYNZ $4.97
- P/E Ratio
- ADN N/A
- MYNZ N/A
- Revenue Growth
- ADN N/A
- MYNZ N/A
- 52 Week Low
- ADN $1.71
- MYNZ $1.34
- 52 Week High
- ADN $8.79
- MYNZ $19.00
- Technical
- Relative Strength Index (RSI)
- ADN 43.59
- MYNZ 57.11
- Support Level
- ADN $1.85
- MYNZ $1.89
- Resistance Level
- ADN $2.50
- MYNZ $2.25
- Average True Range (ATR)
- ADN 0.20
- MYNZ 0.22
- MACD
- ADN 0.03
- MYNZ 0.05
- Stochastic Oscillator
- ADN 21.54
- MYNZ 76.14
About ADN Advent Technologies Holdings Inc.
Advent Technologies Holdings Inc is an innovation-driven company in the fuel cell and hydrogen technology space. The company develops, manufactures, and assembles complete fuel cell systems and the critical components that determine the performance of hydrogen fuel cells and other energy systems. It serves automotive; aviation and power generation industries. It generates revenue from the sale of fuel cell systems and the sale of MEAs, membranes, and electrodes for specific applications in the fuel cell and energy storage (flow battery) markets.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.